US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Niagen Bioscience

4.41

+0.13003.04%

Post-market: 4.410.00000.00%19:59 EDT

Volume:723.54K

Turnover:3.20M

Market Cap:352.45M

PE:22.05

High:4.54

Open:4.36

Low:4.34

Close:4.28

52wk High:14.69

52wk Low:4.16

Shares:79.92M

Float Shares:51.41M

Volume Ratio:0.81

T/O Rate:1.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2000

EPS(LYR):0.2000

ROE:28.35%

ROA:10.23%

PB:4.61

PE(LYR):22.05

Loading ...

Overview Company News Filings

Niagen Bioscience up 39% at $6.88 after Q4 results and guidance

Niagen Bioscience Q4 net sales rise

Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion

Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate

Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million

BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million

Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%

THOMSON REUTERS

Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 Million, 103% Net Income Increase to $17.4 Million or $0.22 Basic EPS in 2025

THOMSON REUTERS

Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash

Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction

THOMSON REUTERS

Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal

THOMSON REUTERS

BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside

Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside

THOMSON REUTERS

Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations

Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen

Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?

Simply Wall St.

Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026

BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen

Niagen Bioscience Inc - Partners With Truemed to Expand Hsa/FSA Access for Tru Niagen

THOMSON REUTERS

Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NAGE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAGE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":4.41,"timestamp":1774987200000,"preClose":4.28,"halted":0,"volume":723537,"hourTrading":{"tag":"盘后","latestPrice":4.41,"preClose":4.41,"latestTime":"19:59 EDT","volume":22449,"amount":99001.5803,"timestamp":1775001572109,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.030373831775700907,"floatShares":51414700,"shares":79919957,"eps":0.2,"marketStatus":"Closed","change":0.13,"latestTime":"03-31 16:00:00 EDT","open":4.36,"high":4.5399,"low":4.34,"amount":3195125.8618581,"amplitude":0.046706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775030400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":4.28,"preHourTrading":{"tag":"盘前","latestPrice":4.27,"preClose":4.28,"latestTime":"09:27 EDT","volume":312,"amount":1312.6337640000002,"timestamp":1774963670025,"change":-0.01,"changeRate":-0.002336,"amplitude":0.031005},"postHourTrading":{"tag":"盘后","latestPrice":4.41,"preClose":4.41,"latestTime":"19:59 EDT","volume":22449,"amount":99001.5803,"timestamp":1775001572109,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.805964,"impliedVol":3.8149,"impliedVolPercentile":0.9721},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAGE\",,,,,undefined,":{"symbol":"NAGE","floatShares":51414700,"roa":"10.23%","roe":"28.35%","lyrEps":0.2,"volumeRatio":0.805964,"shares":79919957,"dividePrice":0,"high":4.5399,"amplitude":0.046706,"preClose":4.28,"low":4.34,"week52Low":4.16,"pbRate":"4.61","psRate":"2.72","week52High":14.69,"institutionHeld":0,"latestPrice":4.41,"eps":0.2,"divideRate":0,"volume":723537,"delay":0,"ttmEps":0.2,"open":4.36,"prevYearClose":6.36,"prevWeekClose":4.2,"prevMonthClose":5.05,"prevQuarterClose":6.36,"fiveDayClose":4.54,"twentyDayClose":4.87,"sixtyDayClose":6.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAGE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-04","symbol":"NAGE","fiscalQuarterEnding":"2025/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1772600400000,"reportTimeType":"post","actualEps":0.03},{"market":"US","date":"2025-11-04","symbol":"NAGE","fiscalQuarterEnding":"2025/09","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":0.05},{"market":"US","date":"2025-08-06","symbol":"NAGE","fiscalQuarterEnding":"2025/06","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-05-07","symbol":"NAGE","fiscalQuarterEnding":"2025/03","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":0.04},{"market":"US","date":"2025-03-04","symbol":"NAGE","fiscalQuarterEnding":"2024/12","expectedEps":0.02,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAGE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAGE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1748577600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NAGE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NAGE","date":"2026-03-30","current":21.4,"percent":0.011673,"low":19.052974,"twenty":24.737504,"median":42.509176,"eighty":62.36748,"high":80.643552,"avg":42.80571,"sd":18.660911,"marketCap":337039449},"quantilePoints":[{"date":"2025-03-21","current":69.624479,"twenty":69.806742,"median":70.080136,"eighty":70.353531,"marketCap":595289295},{"date":"2025-03-28","current":67.346191,"twenty":68.676711,"median":69.624479,"eighty":70.371757,"marketCap":575809933},{"date":"2025-04-04","current":60.420196,"twenty":62.662031,"median":67.938546,"eighty":69.697384,"marketCap":516592673},{"date":"2025-04-11","current":51.67157,"twenty":54.861173,"median":62.880747,"eighty":69.551574,"marketCap":441791924},{"date":"2025-04-17","current":59.600012,"twenty":54.815607,"median":61.696037,"eighty":69.259953,"marketCap":509580103},{"date":"2025-04-25","current":67.255059,"twenty":55.043436,"median":62.151694,"eighty":68.530901,"marketCap":575030758},{"date":"2025-05-02","current":68.895427,"twenty":55.954751,"median":62.880747,"eighty":69.442216,"marketCap":589055899},{"date":"2025-05-09","current":51.710369,"twenty":55.954751,"median":65.022337,"eighty":70.535794,"marketCap":729374756},{"date":"2025-05-16","current":58.761783,"twenty":54.815607,"median":62.789615,"eighty":69.71561,"marketCap":828834951},{"date":"2025-05-23","current":56.859021,"twenty":55.043436,"median":61.650471,"eighty":69.624479,"marketCap":801996485},{"date":"2025-05-30","current":60.552618,"twenty":55.242319,"median":61.364091,"eighty":69.478669,"marketCap":854094682},{"date":"2025-06-06","current":64.414107,"twenty":55.822209,"median":61.604905,"eighty":69.296406,"marketCap":908560979},{"date":"2025-06-13","current":79.132535,"twenty":56.409541,"median":62.698483,"eighty":70.55402,"marketCap":1116164400},{"date":"2025-06-20","current":77.117845,"twenty":56.623974,"median":63.647427,"eighty":71.912091,"marketCap":1087747202},{"date":"2025-06-27","current":77.341699,"twenty":56.791865,"median":65.523561,"eighty":75.181504,"marketCap":1090904668},{"date":"2025-07-03","current":71.129739,"twenty":57.426855,"median":65.645306,"eighty":75.483707,"marketCap":1003284974},{"date":"2025-07-11","current":65.981088,"twenty":58.471876,"median":66.48476,"eighty":75.192697,"marketCap":930663244},{"date":"2025-07-18","current":57.950311,"twenty":58.471876,"median":65.645306,"eighty":75.114348,"marketCap":817389135},{"date":"2025-07-25","current":51.87826,"twenty":56.758286,"median":65.022337,"eighty":74.190401,"marketCap":731742856},{"date":"2025-08-01","current":52.325969,"twenty":55.224884,"median":64.358143,"eighty":72.732275,"marketCap":738057789},{"date":"2025-08-08","current":43.320593,"twenty":54.318273,"median":62.947882,"eighty":72.15947,"marketCap":768030786},{"date":"2025-08-15","current":43.771379,"twenty":53.985743,"median":62.607352,"eighty":71.628921,"marketCap":776022782},{"date":"2025-08-22","current":44.041851,"twenty":52.415511,"median":61.650471,"eighty":71.37484,"marketCap":780817979},{"date":"2025-08-29","current":44.267244,"twenty":51.68709,"median":61.280145,"eighty":71.129739,"marketCap":784813977},{"date":"2025-09-05","current":42.013311,"twenty":50.71606,"median":60.552618,"eighty":71.083855,"marketCap":744853999},{"date":"2025-09-12","current":43.365671,"twenty":45.745824,"median":60.318517,"eighty":70.845641,"marketCap":768829986},{"date":"2025-09-19","current":45.709762,"twenty":45.222912,"median":59.50888,"eighty":70.6087,"marketCap":810388363},{"date":"2025-09-26","current":42.419019,"twenty":45.024566,"median":58.520194,"eighty":70.371757,"marketCap":752046795},{"date":"2025-10-03","current":33.268051,"twenty":44.46559,"median":56.887002,"eighty":69.697384,"marketCap":589809282},{"date":"2025-10-10","current":34.079467,"twenty":44.02382,"median":56.607185,"eighty":69.623328,"marketCap":604194874},{"date":"2025-10-17","current":33.448366,"twenty":43.66319,"median":55.29204,"eighty":69.583421,"marketCap":593006080},{"date":"2025-10-24","current":33.448366,"twenty":43.41075,"median":54.929521,"eighty":69.405763,"marketCap":593006080},{"date":"2025-10-31","current":32.050928,"twenty":43.28453,"median":54.228731,"eighty":69.187048,"marketCap":568230894},{"date":"2025-11-07","current":25.87441,"twenty":42.455082,"median":54.050915,"eighty":68.822522,"marketCap":528588317},{"date":"2025-11-14","current":27.403352,"twenty":42.022327,"median":53.333314,"eighty":68.390298,"marketCap":559823081},{"date":"2025-11-21","current":26.30565,"twenty":34.151593,"median":52.437896,"eighty":67.731548,"marketCap":537398122},{"date":"2025-11-28","current":26.540872,"twenty":33.854074,"median":52.018169,"eighty":67.346191,"marketCap":542203471},{"date":"2025-12-05","current":26.266446,"twenty":33.628681,"median":51.67157,"eighty":67.255059,"marketCap":536597231},{"date":"2025-12-12","current":25.992021,"twenty":33.448366,"median":50.903505,"eighty":67.255059,"marketCap":530990991},{"date":"2025-12-19","current":25.482373,"twenty":32.772186,"median":49.393282,"eighty":66.988433,"marketCap":520579403},{"date":"2025-12-26","current":25.913613,"twenty":32.474667,"median":46.160548,"eighty":66.182557,"marketCap":529389208},{"date":"2026-01-02","current":24.933522,"twenty":30.002996,"median":45.709762,"eighty":65.94751,"marketCap":509366924},{"date":"2026-01-09","current":25.717595,"twenty":27.520963,"median":45.43929,"eighty":65.757233,"marketCap":525384751},{"date":"2026-01-16","current":24.737504,"twenty":27.019156,"median":45.168818,"eighty":65.594939,"marketCap":505362467},{"date":"2026-01-23","current":24.619893,"twenty":26.909386,"median":44.627874,"eighty":65.546241,"marketCap":502959792},{"date":"2026-01-30","current":23.482987,"twenty":26.540872,"median":44.492638,"eighty":65.122582,"marketCap":479733942},{"date":"2026-02-06","current":20.111473,"twenty":26.282128,"median":44.267244,"eighty":64.478311,"marketCap":410857283},{"date":"2026-02-13","current":19.954658,"twenty":25.944976,"median":44.008043,"eighty":64.391721,"marketCap":407653717},{"date":"2026-02-20","current":19.366604,"twenty":25.843047,"median":43.816458,"eighty":64.134289,"marketCap":395640346},{"date":"2026-02-27","current":20.307491,"twenty":25.623506,"median":43.591065,"eighty":63.1941,"marketCap":414861740},{"date":"2026-03-06","current":23.545172,"twenty":25.529418,"median":43.41075,"eighty":62.988163,"marketCap":409262188},{"date":"2026-03-13","current":22.252496,"twenty":25.411807,"median":43.320593,"eighty":62.862521,"marketCap":386792892},{"date":"2026-03-20","current":21.88316,"twenty":25.058974,"median":43.095199,"eighty":62.753162,"marketCap":380373093},{"date":"2026-03-27","current":20.636651,"twenty":24.761026,"median":42.599334,"eighty":62.487416,"marketCap":358706271},{"date":"2026-03-30","current":19.390142,"twenty":24.737504,"median":42.509176,"eighty":62.36748,"marketCap":337039449}],"updateTime":1774960663275},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAGE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2617646085","title":"Niagen Bioscience up 39% at $6.88 after Q4 results and guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2617646085","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617646085?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:45","pubTimestamp":1772660721,"startTime":"0","endTime":"0","summary":"16:41 EST Niagen Bioscience (NAGE) up 39% at $6.88 after Q4 results and guidance Published first on TheFly – the ultimate source for real-time, mar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/niagen-bioscience-up-39-at-6-88-after-q4-results-and-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569526","title":"Niagen Bioscience Q4 net sales rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569526","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569526?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:12","pubTimestamp":1772658744,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Q4 net sales riseOverviewBioscience company's Q4 net sales rose 16%, beating analyst expectationsNet income for Q4 declined due to higher operating expensesGross margin improved 160 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nL1N3ZS1B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","NAGE","LU0154245673.USD","LU0203347892.USD","LU0154245756.USD","BK4567","BK4121","CMI","BK4183","BK4588","BK4585","LU0203345920.USD","BK4149"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566094","title":"Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566094","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566094?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:06","pubTimestamp":1772658381,"startTime":"0","endTime":"0","summary":"NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/03/51050507/niagen-bioscience-doubles-annual-profit-ceo-signals-acquisition-hunt-and-glp-1-style-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","BK4590","GLP","BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617667425","title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2617667425","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617667425?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658193,"startTime":"0","endTime":"0","summary":"Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 127.27 percent. This is a 44.44 percent decrease over earnings of $0.09 per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51050229/niagen-bioscience-q4-eps-0-05-beats-0-02-estimate-sales-33-839m-beat-31-705m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Niagen Bioscience Q4 EPS $0.05 Beats $0.02 Estimate, Sales $33.839M Beat $31.705M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617456644","title":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617456644","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617456644?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:03","pubTimestamp":1772658183,"startTime":"0","endTime":"0","summary":"Niagen Bioscience posts FY 2025 net income up 2.0x to USD 17.4 million               Niagen Bio reported FY 2025 net sales of USD 129.4 million (+30.0% YoY) and net income of USD 17.4 million (2.0x Yo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL4hvxy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617566458","title":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2617566458","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617566458?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658166,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc Q4 Sales USD 33.839 Million Vs. IBES Estimate USD 31.7 Million\n\n\nMar 04 (Reuters) - Niagen Bioscience Inc Q4 net income USD 4.132 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617569980","title":"Niagen Bioscience Inc Outlook FY Revenue Growth 10-15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617569980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617569980?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nPLXE0E1D6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617661575","title":"Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 Million, 103% Net Income Increase to $17.4 Million or $0.22 Basic EPS in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617661575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617661575?lang=en_us&edition=fundamental","pubTime":"2026-03-05 05:02","pubTimestamp":1772658120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA9TSH7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614045061","title":"Niagen Bioscience Sells ChromaDex Reference Standards Business to LGC for Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045061","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045061?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:07","pubTimestamp":1772107664,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has sold its ChromaDex Reference Standards business to LGC in an all-cash transaction, effective Feb. 24, 2026. The company said the divestiture is intended to streamline operations and sharpen its focus on NAD+ science, intellectual property, and commercial growth in the longevity market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL5PF42V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614045990","title":"Niagen Bioscience to Streamline and Focus Its Operations With the Sale of Chromadex Reference Standards Business to Lgc in All-Cash Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045990","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045990?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614004512","title":"Niagen Bioscience Inc - Sells Chromadex Business to Lgc in All-Cash Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2614004512","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614004512?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:02","pubTimestamp":1772107320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA1LRJV8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614904080","title":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614904080","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614904080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:41","pubTimestamp":1772026883,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Secures New U.S. Patent For Nicotinamide RibosideFeb 25 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - SECURES NEW U.S. PATENT FOR INTRAVENOUS AND INJECTION F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080391","title":"Niagen Bioscience Inc - Secures New U.S. Patent for Intravenous and Injection Formulations & Methods of Use for Nicotinamide Riboside","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080391?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:36","pubTimestamp":1772026594,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL11U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAGE","BK4183","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614080857","title":"Niagen Bioscience Wins New U.S. Patent for IV and Injectable Nicotinamide Riboside Formulations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614080857","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614080857?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:32","pubTimestamp":1772026356,"startTime":"0","endTime":"0","summary":"Niagen Bioscience Inc. said it has been granted U.S. Patent No. 12,558,367, covering methods of use of nicotinamide riboside  and derivatives in intravenous and injectable formulations. The company said the patent adds protection for aqueous formulations, multiple administration routes and parameters, select NR salt forms, and combination use with other NAD+ precursors, with expected protection through 2044.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL2w9L9t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610265588","title":"Niagen Bioscience Sponsors Inaugural NAD for Health Conference in Copenhagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2610265588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610265588?lang=en_us&edition=fundamental","pubTime":"2026-02-09 21:34","pubTimestamp":1770644058,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Niagen Bioscience Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL38XkG6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610957400","title":"Does Niagen Bioscience (NAGE) Still Hold a Defensible NAD+ Moat Ahead of Its 2025 Earnings Call?","url":"https://stock-news.laohu8.com/highlight/detail?id=2610957400","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610957400?lang=en_us&edition=fundamental","pubTime":"2026-02-08 23:10","pubTimestamp":1770563444,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. (NASDAQ: NAGE) previously announced it will report fourth quarter and fiscal 2025 results and host an investor conference call on March 4, 2026, including a general business update following the release of its earnings after market close.\nThe company’s position as a leading NAD+ player, with FDA-recognized Niagen® and defended patents around nicotinamide riboside, highlights a reinforced regulatory moat and product pipeline momentum.\nWe’ll now examine how the upcoming...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-nage/niagen-bioscience/news/does-niagen-bioscience-nage-still-hold-a-defensible-nad-moat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NAGE","NAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609459676","title":"Press Release: Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2609459676","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609459676?lang=en_us&edition=fundamental","pubTime":"2026-02-06 21:32","pubTimestamp":1770384720,"startTime":"0","endTime":"0","summary":"Niagen Bioscience, Inc. , the global authority on NAD+  with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026.Webcast link: Niagen Bioscience Fourth Quarter and Fiscal Year 2025 Earnings Conference Call. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.At the heart of its clinically proven produc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4585","BK4588","R","BK4232","TM","03160","BK4604","NAGE","BK4099","BK4022","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603247988","title":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru Niagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603247988","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603247988?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:37","pubTimestamp":1768484247,"startTime":"0","endTime":"0","summary":"BRIEF-Niagen Bioscience Inc - Partners With Truemed To Expand HSA/FSA Access For Tru NiagenJan 15 (Reuters) - Niagen Bioscience Inc NAGE.O:NIAGEN BIOSCIENCE INC - PARTNERS WITH TRUEMED TO EXPAND HSA/F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603988267","title":"Niagen Bioscience Inc - Partners With Truemed to Expand Hsa/FSA Access for Tru Niagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2603988267","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603988267?lang=en_us&edition=fundamental","pubTime":"2026-01-15 21:36","pubTimestamp":1768484191,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593313431","title":"Niagen's ChromaDex Acquires Nicotinamide Riboside Patents From Queen's University Belfast","url":"https://stock-news.laohu8.com/highlight/detail?id=2593313431","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593313431?lang=en_us&edition=fundamental","pubTime":"2025-12-23 00:42","pubTimestamp":1766421739,"startTime":"0","endTime":"0","summary":"Niagen Bioscience  said Monday its ChromaDex subsidiary has acquired from Queen's University Belfast the patent portfolio for nicotinamide riboside previously shared or licensed to ChromaDex.Under an assignment agreement, the university assigned to ChromaDex all of its right, title and interest in the patent rights in exchange for an upfront payment of about $1 million, annual payments of $500,000 and 35,000 British pounds  from 2026 through 2038, and one-time payments of $1.5 million and $2 million in 2035 and 2038 respectively, Niagen said in its filing with the US Securities and Exchange Commission.Niagen said the acquired portfolio consists of the core patents supporting the production, composition and commercial use of nicotinamide riboside.The assignment agreement, executed by ChromaDex and the university last week, terminated their 2015 licensing and joint ownership agreement, Niagen said.Shares of Niagen were up more than 7% in recent Monday trading.Price: 6.98, Change: +0.46, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":78,"code":"91000000","status":"200"}]}}